A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
NCT ID: NCT04605159
Last Updated: 2025-02-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
11194 participants
INTERVENTIONAL
2020-11-20
2023-06-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in the study. Ongoing study participants at that time continued to be monitored as part of the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
NCT04980391
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
NCT05705440
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
NCT05045144
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
NCT04424316
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
NCT04886596
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RSV MAT Group - Mother
Maternal participants received a single dose of the RSV MAT vaccine administered at Day 1 in this study.
RSV MAT
One dose of RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm at Day 1.
Placebo Group - Mother
Maternal participants received a single dose of placebo administered at Day 1 in this study.
Placebo
One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
RSV MAT Group - Infant
This group consisted of infants born to mothers (from RSV MAT Group - Mother) who received a single dose of RSV MAT vaccine during pregnancy.
No interventions assigned to this group
Placebo Group - Infant
This group consisted of infants born to mothers (from Placebo Group - Mother) who received a single dose of placebo during pregnancy.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RSV MAT
One dose of RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm at Day 1.
Placebo
One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Participants who give written or witnessed/thumb printed informed consent after the study has been explained, and before any study specific procedures are performed, as per local regulations regulatory requirements.
* Age 18 to 49 years, inclusive, at the time of study intervention.
* Pre-pregnancy BMI 17.0 to 39.9 kg/m2, inclusive.
* In good general maternal health as established by medical history and clinical examination before entering into the study.
* Singleton pregnancy (including instances where the singleton pregnancy derives from a vanishing twin syndrome).
* At 24\^0/7 to 34\^0/7 weeks of gestation at the time of study vaccination (Visit 1), as established by:
* last menstrual period (LMP) date corroborated by first or second trimester ultrasound examination (U/S) i.e. at or before 28 weeks of gestation.
* 1st or 2nd trimester U/S only, if LMP is unknown/uncertain
* Certain LMP, corroborated by an U/S performed after 28 weeks of gestation is also acceptable.
* No fetal genetic abnormalities (based on genetic testing, if performed).
* No significant congenital malformations, as assessed by fetal anomaly ultrasound scan conducted at or beyond 18 weeks of gestation.
* Willing to provide cord blood.
* Who do not plan to give their child for adoption.
* Who plan to reside in the study area for at least one year after delivery.
* Willing to have the infant followed-up after delivery for a period of 12 months.
Infant participants
* Live-born from the study pregnancy.
* If required per local regulations/guidelines, re-signed (confirmed) written or witnessed/thumb printed informed consent for study participation of the infant obtained from the infant's mother and/or father and/or LAR, before performing any study specific procedure. OR, if permitted by local regulation, documented verbal consent for infant's participation obtained from the parent(s)/LAR(s) at birth, followed by written consent obtained by (or before) Visit 2-newborn.
Exclusion Criteria
* History of allergic disease or reactions likely to be exacerbated by any component of the RSV vaccine
* Hypersensitivity to latex
* Significant complications in the current pregnancy:
* Gestational hypertension unless blood pressure it is controlled and maintained in the normal range (\<140mmHg and \<90mmHg) through diet and/or antihypertensive medications
* Gestational diabetes not controlled by medication, diet and/or exercise
* Pre-eclampsia
* Eclampsia
* Intrauterine Growth Restriction/Fetal Growth Restriction
* Placenta previa
* Placental abruption, placenta accreta/percreta/increta, chorioamnionitis or any abnormalities that can impair the maternal-fetal circulation
* Polyhydramnios
* Oligohydramnios
* Preterm labour or history of preterm labour in the current pregnancy
* Any intervention to prevent preterm delivery or medical treatment for suspected preterm delivery, including administration of systemic corticosteroids for fetal lung maturation
* Cholestasis
* Other pregnancy-related complications (per investigator's judgement)
* Significant structural abnormalities of the uterus or cervix
* History of 2 or more prior stillbirths or neonatal deaths/history of 2 or more preterm births at ≤34 weeks gestation/3 or more consecutive spontaneous abortions
* Known HIV infection (as per serological tests performed during the current pregnancy)
* Known or suspected HBV or HCV infection
* Known or suspected infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Zika, Rubella, Varicella, CMV or primary genital Herpes Simplex
* Active infection with tuberculosis
* Known or suspected impairment of the immune system
* Current autoimmune disorder for which the participant has received immune-modifying therapy within 6 months before study vaccination, or plans administration through delivery
* Lymphoproliferative disorder or malignancy within 5 years before study vaccination
* Acute or chronic clinically significant abnormality or poorly controlled pre-existent co-morbidities or any other clinical conditions that might pose additional risk to the participant due to participation in the study
* Any conditions that may interfere with participant's ability to comply with study procedures or receipt of prenatal care
* Any condition which would increase the risks of study participation to the unborn infant
Prior/Concomitant therapy
* Prior receipt of an RSV vaccine in the current pregnancy
* Use of any investigational/non-registered product other than the study vaccine/product as described below, or planned use during the period :
* For a drug, vaccine or medical device: from 29 days before the dose of study vaccine
* For immunoglobulins: 3 months before the dose of study vaccine/product.
The exception to this is investigational products administered in the setting of a pandemic which may be allowed following delivery
* Planned administration/administration of any vaccine from 29 days before the dose of study vaccine or planned administration through delivery, except:
* Seasonal influenza vaccines, tetanus vaccines, dTpa/Tdap - alone vaccines, dTpa/Tdap vaccines that also contain other antigens, Hepatitis B vaccines, and COVID-19 vaccines all of which may be administered according to standard of care ≥15 days before or after study vaccination
* Administration of immunoglobulins (except anti-Rh0D IG, which may be administered at any time), blood products or plasma derivatives within 3 months before study vaccination or planned administration through delivery
* Administration of immune-modifying therapy within 6 months before the study vaccination, or planned administration through delivery. This includes but is not limited to:
* Azathioprine, mycophenolate mofetil, 6-mercaptopurine, cyclosporine, tacrolimus, monoclonal or polyclonal antibodies
* Prednisone ≥5 mg/day or equivalent for ≥14 days; Inhaled, intra-articular/intra-bursal and topical steroids are allowed
* Corticosteroids administered for fetal lung maturation
Prior/Concurrent clinical study experience
\- Concurrently participating in another clinical study, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product
Other exclusions
* Alcoholism or substance use disorder within the past 24 months based on DSM-5 criteria
* A local condition that precludes injection of the study vaccine/product or precludes assessment of local reactogenicity
* Consanguinity of maternal participant and her partner (second degree cousins or closer)
* Any study personnel or their immediate dependants, family or household members
Infant participants
* Concurrently participating in another clinical study, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product
* Any condition which would increase the risks of study participation to the infant
* Child in care.
18 Years
49 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Dothan, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Burbank, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Blackfoot, Idaho, United States
GSK Investigational Site
Idaho Falls, Idaho, United States
GSK Investigational Site
Nampa, Idaho, United States
GSK Investigational Site
Nampa, Idaho, United States
GSK Investigational Site
Covington, Louisiana, United States
GSK Investigational Site
Lafayette, Louisiana, United States
GSK Investigational Site
Slidell, Louisiana, United States
GSK Investigational Site
Detroit, Michigan, United States
GSK Investigational Site
Saginaw, Michigan, United States
GSK Investigational Site
Missoula, Montana, United States
GSK Investigational Site
Grand Island, Nebraska, United States
GSK Investigational Site
Lincoln, Nebraska, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
Englewood, Ohio, United States
GSK Investigational Site
Greenville, South Carolina, United States
GSK Investigational Site
Hendersonville, Tennessee, United States
GSK Investigational Site
Arlington, Texas, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Burleson, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Fort Worth, Texas, United States
GSK Investigational Site
Georgetown, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Keller, Texas, United States
GSK Investigational Site
Lampasas, Texas, United States
GSK Investigational Site
League City, Texas, United States
GSK Investigational Site
McAllen, Texas, United States
GSK Investigational Site
Mesquite, Texas, United States
GSK Investigational Site
Plano, Texas, United States
GSK Investigational Site
Weatherford, Texas, United States
GSK Investigational Site
Norfolk, Virginia, United States
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Ciudad AutOnoma de Buenos Aire, , Argentina
GSK Investigational Site
Ciudad AutOnoma de Buenos Aire, , Argentina
GSK Investigational Site
Córdoba, , Argentina
GSK Investigational Site
San Miguel de Tucumán, , Argentina
GSK Investigational Site
South Brisbane, Queensland, Australia
GSK Investigational Site
Southport, Queensland, Australia
GSK Investigational Site
Clayton, Victoria, Australia
GSK Investigational Site
Geelong, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Matlab, , Bangladesh
GSK Investigational Site
Sylhet, , Bangladesh
GSK Investigational Site
Genk, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Kortrijk, , Belgium
GSK Investigational Site
Leuven, , Belgium
GSK Investigational Site
Sint-Niklaas, , Belgium
GSK Investigational Site
Caxias do Sul, , Brazil
GSK Investigational Site
Nova Iguaçu, , Brazil
GSK Investigational Site
Porto Alegre, , Brazil
GSK Investigational Site
RibeirAo PretoSP, , Brazil
GSK Investigational Site
Santa Maria, , Brazil
GSK Investigational Site
São José do Rio Preto, , Brazil
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Kingston, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Barranquilla, , Colombia
GSK Investigational Site
Bogotá, , Colombia
GSK Investigational Site
Cali Colombia, , Colombia
GSK Investigational Site
Chía, , Colombia
GSK Investigational Site
Medellín, , Colombia
GSK Investigational Site
Medellín, , Colombia
GSK Investigational Site
Santo Domingo Este, , Dominican Republic
GSK Investigational Site
Helsinki, , Finland
GSK Investigational Site
Kokkola, , Finland
GSK Investigational Site
Oulu, , Finland
GSK Investigational Site
Tampere, , Finland
GSK Investigational Site
Turku, , Finland
GSK Investigational Site
Bordeaux, , France
GSK Investigational Site
Clermont-Ferrand, , France
GSK Investigational Site
Montpellier, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Pierre-Bénite, , France
GSK Investigational Site
Comayagua, , Honduras
GSK Investigational Site
San Pedro Sula, , Honduras
GSK Investigational Site
Kolkata, , India
GSK Investigational Site
Mangalore, , India
GSK Investigational Site
Mysore, , India
GSK Investigational Site
Nagpur, , India
GSK Investigational Site
Pune, , India
GSK Investigational Site
Vadu Budruk Pune, , India
GSK Investigational Site
Bari, , Italy
GSK Investigational Site
Messina, , Italy
GSK Investigational Site
Milan, , Italy
GSK Investigational Site
Milan, , Italy
GSK Investigational Site
Milan, , Italy
GSK Investigational Site
Milan, , Italy
GSK Investigational Site
Novara, , Italy
GSK Investigational Site
Palermo, , Italy
GSK Investigational Site
Prato, , Italy
GSK Investigational Site
Verona, , Italy
GSK Investigational Site
Chihuahua City, , Mexico
GSK Investigational Site
Monterrey, , Mexico
GSK Investigational Site
Monterrey, , Mexico
GSK Investigational Site
Morelia, , Mexico
GSK Investigational Site
Oaxaca City, , Mexico
GSK Investigational Site
San Juan del Río, , Mexico
GSK Investigational Site
San Luis Potosí City, , Mexico
GSK Investigational Site
Grafton Auckland, , New Zealand
GSK Investigational Site
Papatoetoe Auckland, , New Zealand
GSK Investigational Site
Wellington, , New Zealand
GSK Investigational Site
Panama City, , Panama
GSK Investigational Site
Panama City, , Panama
GSK Investigational Site
Panama City, , Panama
GSK Investigational Site
Panama City, , Panama
GSK Investigational Site
Cavite, , Philippines
GSK Investigational Site
Manila, , Philippines
GSK Investigational Site
Manila, , Philippines
GSK Investigational Site
Johannesburg, , South Africa
GSK Investigational Site
Pretoria, , South Africa
GSK Investigational Site
Soshanguve, , South Africa
GSK Investigational Site
Soweto, , South Africa
GSK Investigational Site
Daegu, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Aravaca, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Bilbao, , Spain
GSK Investigational Site
Boadilla Del Monte Madrid, , Spain
GSK Investigational Site
Burgos, , Spain
GSK Investigational Site
Getafe, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Marbella, , Spain
GSK Investigational Site
Málaga, , Spain
GSK Investigational Site
Málaga, , Spain
GSK Investigational Site
Seville, , Spain
GSK Investigational Site
Seville, , Spain
GSK Investigational Site
TorrejOn Ardoz Madrid, , Spain
GSK Investigational Site
Valencia, , Spain
GSK Investigational Site
Valencia, , Spain
GSK Investigational Site
Valladolid, , Spain
GSK Investigational Site
Changhua, , Taiwan
GSK Investigational Site
Kaohsiung City, , Taiwan
GSK Investigational Site
Taichung, , Taiwan
GSK Investigational Site
Taipei, , Taiwan
GSK Investigational Site
Taipei, , Taiwan
GSK Investigational Site
Taipei, , Taiwan
GSK Investigational Site
Taoyuan District, , Taiwan
GSK Investigational Site
Bangkok, , Thailand
GSK Investigational Site
Chiang Mai, , Thailand
GSK Investigational Site
Edinburgh, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dieussaert I, Hyung Kim J, Luik S, Seidl C, Pu W, Stegmann JU, Swamy GK, Webster P, Dormitzer PR. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes. N Engl J Med. 2024 Mar 14;390(11):1009-1021. doi: 10.1056/NEJMoa2305478.
Banooni P, Gonik B, Epalza C, Reyes O, Madhi SA, Gomez-Go GD, Zaman K, Llapur CJ, Lopez-Medina E, Stanley T, Kantele A, Huang LM, Mussi-Pinhata MM, Dewulf J, Langley JM, Seidl C, Ota M, Kirabo M, Anspach B, Dieussaert I, Henry O, Kim JH, Picciolato M. Efficacy, immunogenicity, and safety of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine. Clin Infect Dis. 2025 Jan 29:ciaf033. doi: 10.1093/cid/ciaf033. Online ahead of print.
Ginsburg AS, Srikantiah P. Respiratory syncytial virus: promising progress against a leading cause of pneumonia. Lancet Glob Health. 2021 Dec;9(12):e1644-e1645. doi: 10.1016/S2214-109X(21)00455-1. Epub 2021 Nov 11. No abstract available.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-001355-40
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
212171
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.